Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
已完成
1
50.0%
暂停
1
50.0%
暂无批准数据
- Edesa Biotech is preparing to initiate a Phase 2 trial of EB06, an anti-CXCL10 monoclonal antibody, for moderate-to-severe non-segmental vitiligo patients in mid-2026. - The planned study will enroll approximately 160 patients and evaluate three different doses of EB06 administered intravenously every two weeks for up to 24 weeks. - Updated Phase 3 ARDS results showed paridiprubart achieved a 27% relative reduction in 28-day mortality risk compared to placebo in the full 278-patient population. - The vitiligo market is projected to reach approximately $1.2 billion by 2030, with current treatment options limited to topical ruxolitinib carrying black-box warnings.
- DelveInsight's 2026 pipeline analysis reveals over 50 companies actively developing more than 50 investigational therapies for acute respiratory distress syndrome treatment. - Leading drug candidates include STSA-1002 (complement C5a inhibitor), GEn 1124 (MAPK14 inhibitor), and ALT-100 (eNAMPT inhibitor), spanning various mechanisms of action and development stages. - Recent clinical milestones include Edesa Biotech's positive Phase III results for paridiprubart and FDA Fast Track designations for multiple ARDS therapies. - The pipeline demonstrates significant therapeutic diversity with approximately 20 drugs in mid-stage development and 22 in early-stage trials.
- Edesa Biotech's anti-TLR4 antibody paridiprubart demonstrated a statistically significant 27% relative reduction in 28-day mortality risk in a Phase 3 study of 278 ARDS patients. - The treatment reduced adjusted mortality from 33% to 24% across the full population and showed consistent benefits in patients with serious comorbidities including sepsis, pneumonia, and acute kidney injury. - Based on these results, Edesa has filed provisional patent applications for paridiprubart's use in treating sepsis, acute kidney injury, and pneumonia while advancing regulatory discussions and partnership opportunities.
- Edesa Biotech is preparing to initiate a Phase 2 trial of EB06, an anti-CXCL10 monoclonal antibody, for moderate-to-severe non-segmental vitiligo patients by mid-2026. - The planned study will enroll approximately 160 patients and evaluate three different doses of EB06 administered intravenously every two weeks for up to 24 weeks. - With only one FDA-approved vitiligo treatment carrying a black-box warning, EB06 addresses a significant unmet medical need in a market projected to reach $1.1 billion by 2030. - The company has already received Health Canada approval for the Phase 2 trial and initiated manufacturing activities to supply drug product for the study.
- Paridiprubart demonstrated a statistically significant 25% relative reduction in death risk at 28 days compared to placebo in patients with Acute Respiratory Distress Syndrome (ARDS). - The Phase 3 study met both primary and secondary endpoints, showing durable survival benefits through 60 days and reduced need for invasive mechanical ventilation. - The host-directed therapeutic exhibited consistent safety and tolerability across more than 275 subjects, supporting its potential as a standard of care treatment for ARDS. - Paridiprubart works by inhibiting toll-like receptor 4 (TLR4), representing a novel therapeutic approach that is agnostic to the underlying cause of respiratory distress.
- DelveInsight's 2025 pipeline assessment reveals three key companies are developing novel hemorrhoids treatment therapies, with emerging drugs like EB02, Halo-Lido, and Hydrocortisone Acetate Suppository expected to significantly impact the market. - Citius Pharmaceuticals completed a Phase 2b trial for Halo-Lido (CITI-002) in 2023 and applied for patents in June 2023, positioning the topical formulation as a promising treatment for hemorrhoid relief. - The hemorrhoids treatment market faces growth drivers including rising awareness and increased reported cases, while barriers include lack of specialized healthcare infrastructure and time-consuming treatment procedures.
- Edesa Biotech is preparing to submit regulatory data to FDA for EB06, an anti-CXCL10 monoclonal antibody targeting vitiligo, with submissions planned for mid-2025. - The company secured $15 million in gross proceeds through a private placement, strengthening its position to advance the vitiligo program through clinical development. - Phase 2 clinical trial for moderate-to-severe nonsegmental vitiligo patients is anticipated to deliver topline results within 12-18 months after FDA clearance.
- Edesa Biotech strategically shifted its anti-TLR4 drug candidate (EB05) towards a U.S. government-funded study for Acute Respiratory Distress Syndrome (ARDS) treatment. - The company reduced operating expenses by over 20%, decreasing total expenses to $7.0 million from $9.2 million year-over-year, showcasing effective financial management. - Despite a net loss of $6.2 million, Edesa secured $2.1 million in post-fiscal year funding, enhancing its financial position for future development and strategic opportunities. - Edesa anticipates topline results for its Phase 2 vitiligo study within 12-18 months after regulatory clearance, contingent on securing adequate funding.
